Docs Who Lift

Dr. Karin Norton, a behavior change scientist and founder of Body Brain Alliance, dives into building healthy routines that last. She reveals that motivation is a skill developed through self-efficacy and discusses the crucial difference between true habits and routine behaviors. Karin emphasizes the importance of aligning actions with long-term goals using future self-thinking. She shares practical strategies for lowering barriers, breaking tasks into small steps, and modeling healthy behaviors for children, debunking common myths in the process.

Dr. Susan Davis, an esteemed Australian endocrinologist specializing in testosterone therapy and women's health, dives deep into the complexities of low libido. She reveals that testosterone can significantly enhance postmenopausal women's sexual desire but emphasizes the importance of individualized care. Davis discusses the role of psychosocial factors and debunks myths about low testosterone at menopause. With insights on dosing and the placebo effect, she clarifies that current therapies primarily support those with distressing low desire, not other health claims.

Dr. Sean Wharton, a leading clinical trialist and PharmD, shares insights on the latest developments in oral GLP-1 therapies. He explains the intriguing 'snack molecule' concept that improves drug delivery and discusses the promising results of the OASIS-4 trial, showcasing significant weight loss. The conversation covers the differences between peptide and small-molecule GLP-1s and the future potential of orforglipron. They also highlight the importance of safety in new formulations and how these advances could democratize weight management.

Discover the shift towards a person-centered approach in obesity care as experts break down the new ACE Algorithm. They explore the importance of a staging system that personalizes treatment and the significant role of lifestyle factors like resistance training and sleep. Learn about realistic weight loss targets and how they correlate with health impacts. Insightful discussions on medication selection and understanding obesity's complex nature make this a must-listen for professionals and patients alike.

In this conversation, nutrition researcher Kevin Hall and science journalist Julia Belluz tackle myths about metabolism and weight loss. They reveal how media miscommunication has shaped public perceptions, particularly related to the Biggest Loser study. Kevin explains metabolic adaptation and its role in weight regain, while Julia emphasizes the cultural factors influencing eating habits. They also discuss the significant impact of food environments and the need for bipartisan policy changes to improve dietary health.

Takeaways Menopausal women often prioritize weight gain concerns over other symptoms.The study observed an association between hormone therapy and weight loss with GLP-1 medications.Retrospective studies have limitations but can provide valuable insights.Future research should focus on randomized controlled trials to confirm findings.The relationship between estrogen and GLP-1 signaling needs further exploration.Funding for research can be challenging, especially for early career investigators.Collaboration between different specialties is crucial for comprehensive patient care.The media often misrepresents research findings, leading to misconceptions.Individualized treatment plans are essential for menopausal women.There is a need for more awareness about the effects of menopause on health.Research Links:Weight loss response to semaglutide in postmenopausal women with and without hormone therapy useCombination of obesity medication tirzepatide and menopause hormone therapy fuels weight loss   Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Join Dr. Stacy Sims, an environmental exercise physiologist known for her groundbreaking work on sex differences in fitness, and Dr. Lauren Colenso-Semple, a leading researcher on muscle growth and the effects of hormonal cycles. They dive into fasted training and its unique implications for women, the importance of post-workout nutrition considering hormonal influences, and tailored strength training for those in perimenopause. They also discuss the evolving landscape of women's health research, advocating for individualized and evidence-based fitness strategies.

In this discussion, body composition expert Grant Tinsley shares valuable insights on GLP-1 receptor agonists like semaglutide and tirzepatide. He highlights the remarkable body composition changes observed in patients, illustrating how one lost significant fat while preserving lean mass. The importance of resistance training and proper nutrition in weight management takes center stage. Tinsley emphasizes the need for more randomized trials to deepen understanding, all while underscoring individual experiences with these innovative weight loss treatments.

Austin Baraki and Jordan Feigenbaum, physicians from Barbell Medicine, dive into the risks of direct-to-consumer lab testing. They discuss alarming marketing tactics that prey on patient anxieties and the pitfalls of inadequate communication within healthcare. The duo highlights the rise of unqualified influencers promoting questionable lab services and the dangers of misinterpretation of results. They call for ethical practices in testing, emphasizing the need for thorough professional evaluation and collaboration to improve patient outcomes.

In this episode of the Dr. Lift podcast, hosts Dr. Spencer Nadolsky and Dr. Karl discuss the recent changes in obesity medication coverage, particularly focusing on the CVS Caremark decision to drop ZEPBound from their formulary in favor of Wegovi. They explore the implications of this decision for patients and providers, the role of pharmacy benefit managers (PBMs) in healthcare, and the ongoing advocacy efforts to ensure access to effective obesity treatments. The conversation highlights the complexities of insurance coverage, the need for patient-centered care, and the importance of making medications more affordable.- The recent changes in obesity medication coverage have raised concerns among providers and patients.- CVS Caremark's decision to drop ZEPBound has sparked a petition advocating for better access to medications.- Pharmacy Benefit Managers (PBMs) play a significant role in determining medication coverage and costs.- There is a need for more nuanced insurance policies that consider patient needs and clinical severity.- Advocacy efforts are crucial in reversing negative trends in medication coverage.- Patients often face challenges with prior authorization processes when switching medications.- The cost of obesity medications is a significant barrier to access for many patients.- Insurance companies are increasingly dropping coverage for anti-obesity medications, impacting patient care.- The conversation emphasizes the importance of patient-centered care in obesity treatment.- There is a call for making obesity medications more affordable and accessible to patients.https://www.change.org/p/stop-cvs-caremark-s-zepbound-ban-restore-coverage-of-the-superior-obesity-medicationClick to join Dr. Spencer's online clinic if you need help with this  Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.